| 2024/04/18 | |
|---|---|
| NAV | |
| 12,464.6000 | |
| Difference | -0.65% (-81.93) |
General attributes
| Fund type | Equity Funds |
| Investment company | Erste Asset Management GmbH |
| Currency | CZK |
| Type | VT |
| Begin of subscription period | - |
| Inception | 2000/04/17 |
| Licenced in | AT,CZ |
| Duration of fund | open end |
| Total assets | 233,227,566.80 EUR |
| Fiscal year | 03/15 - 03/14 |
| Initial charge | 3.00% |
| Management fee | 1.80% |
| Ongoing charges | 2.07% |
| Minimum investment | According to offer |
| Account number | - |
| Recommended holding period | At least 6 years |
| Investor experience | - |
| Investor tolerance | 5 (scale 1-7) |
| Disclosure Regulation | Article 8 |
Fund PDF download
| Prospectus |  |
| Key Information Document (KID) | |
| Sustainability-related disclosures | |
| CZ Flyer | |
| Target market information | |
| CZ Disclaimer | |
Fund annual reports
| Annual Reports | 2023/03/14 | |
| First-Half Report | 2023/09/14 | |
Scale: ABS REL
The chart shows the current fund share unit price (NAV) of the nominal value of an investment company proclaimed on that working day. Performances under 12 month have only little informative value. Information about previous performance does not guarantee future performance.
Source: Česká spořitelna, a. s.
| Advantages | Details you should be aware of |
| Broadly diversified investment in biotechnology companies with little capital investment. Active stock selection based on fundamental criteria. Opportunities for capital appreciation. The fund is suitable as an addition to an existing equity portfolio and is intended for long-term capital appreciation. | The price of the fund can fluctuate considerably (high volatility). Due to the investment in foreign currencies the net asset value in Euro can fluctuate due to changes in the exchange rate. Capital loss is possible. Risks that may be significant for the fund are in particular: credit and counterparty risk, liquidity risk, custody risk, derivative risk and operational risk. Comprehensive information on the risks of the fund can be found in the prospectus or the information for investors pursuant to § 21 AIFMG, section II, "Risk information". |
Secondary market
Purchase of share certificates |
Disclaimer
| The full names of the open-ended mutual funds and complete product information are provided in the statutes (prospectuses) of the funds. The information stated herein is of the nature of a promotional message. The information stated in this message is not an investment recommendation or investment advice since it does not take into account the specific situation of specific investors. The value of the financial instruments may rise and fall, while there is no guarantee of a return on the originally invested amount. Past performance is no guarantee of the same performance in a future period. A visitor to this website may be outside the target market of the financial instruments stated herein. We recommend that you consult your specific investment plan with an expert advisor who will verify that the planned investment will be commensurate with your knowledge and experience, that it will be in accordance with your needs, characteristics and goals, financial circumstances or relation to risk, and will familiarise you with all possible risks of a specific investment opportunity. |
Performance goal and investment strategy
| The ERSTE STOCK BIOTEC invests primarily in companies in the developed markets from the field of biotechnology. The fund's investment process is based on fundamental business analysis. The majority of companies in this area can be found in the United States. As a result, Pacific and European equities tend to play a subordinated role in the fund. A hedge against foreign currency risks is generally not provided, but is possible. |
Performance (2024/03/28)
| Period | YTD |
6m |
1Y (% p a) |
3Y (% p a) |
5Y (% p a) |
10Y (% p a) |
since inc. (% p a) |
| Perf | 4.99 | - | 16.87 | -0.69 | 0.65 | 6.09 | 10.17 |
Annual performance in % (-)
| Period | 2019 | 2020 | 2021 | 2022 | 2023 |
| Perf | 32.21 | 14.45 | 7.89 | -4.73 | 3.72 |
Statistical figures (2024/03/28)
| Sharpe Ratio | - |
| Volatility in % | 16.38 |
Minimum & maximum performance in % p.a. (2024/03/28)
| 1Y | 117.38  |
 -51.90 | |
| 3Y | 52.56 |
-22.95 | |
| 5Y | 42.14 |
-9.64 | |
| 10Y | 21.55 |
-4.24 |
Disclaimer
| The full names of the open-ended mutual funds and complete product information are provided in the statutes (prospectuses) of the funds. The information stated herein is of the nature of a promotional message. The information stated in this message is not an investment recommendation or investment advice since it does not take into account the specific situation of specific investors. The value of the financial instruments may rise and fall, while there is no guarantee of a return on the originally invested amount. Past performance is no guarantee of the same performance in a future period. A visitor to this website may be outside the target market of the financial instruments stated herein. We recommend that you consult your specific investment plan with an expert advisor who will verify that the planned investment will be commensurate with your knowledge and experience, that it will be in accordance with your needs, characteristics and goals, financial circumstances or relation to risk, and will familiarise you with all possible risks of a specific investment opportunity. |
Top holdings (2024/03/28)
| ISIN | Name | Currency | %FA |
| - | REGENERON PHARMAC.DL-,001 | - | 9.37 |
| - | ASTRAZENECA DL-,25 SP.ADR | - | 7.86 |
| - | VERTEX PHARMAC. DL-,01 | - | 7.73 |
| - | GILEAD SCIENCES DL-,001 | - | 7.50 |
| - | BIOGEN INC. DL -,0005 | - | 5.13 |
| - | AMGEN INC. DL-,0001 | - | 4.65 |
| - | BIOMARIN PHAR. DL-,001 | - | 2.99 |
| - | ARGENS SE SP.ADR/1 -,10 | - | 2.65 |
| - | MADRIGAL PHARMAC. DL-,01 | - | 2.50 |
| - | SAREPTA THERAP. DL-,0001 | - | 2.14 |
Holdings by country (2024/03/28)
 | 85.30 % | United States of America |
| 8.50 % | United Kingdom |
| 2.92 % | Netherlands |
| 1.09 % | Denmark |
Percentage holdings by sector (2024/03/28)
| 83.63 % | Biotechnology |
| 12.83 % | Pharmaceuticals |
| 2.96 % | Life Sciences Tools & Services |
| 0.59 % | Health Care Services |
Holdings by currency (2024/03/28)
| 103.20 % | USD |
| -3.20 % | EUR |
Disclaimer
| The full names of the open-ended mutual funds and complete product information are provided in the statutes (prospectuses) of the funds. The information stated herein is of the nature of a promotional message. The information stated in this message is not an investment recommendation or investment advice since it does not take into account the specific situation of specific investors. The value of the financial instruments may rise and fall, while there is no guarantee of a return on the originally invested amount. Past performance is no guarantee of the same performance in a future period. A visitor to this website may be outside the target market of the financial instruments stated herein. We recommend that you consult your specific investment plan with an expert advisor who will verify that the planned investment will be commensurate with your knowledge and experience, that it will be in accordance with your needs, characteristics and goals, financial circumstances or relation to risk, and will familiarise you with all possible risks of a specific investment opportunity. |
